SFRP4 Is a Potential Biomarker for the Prognosis and Immunotherapy for Gastric Cancer

Table 4

Univariate analysis of prognostic parameters for survival in gastric cancer patients.

Variable	Univariable analysis
	HR (95% CI)	value^c
SFRP4 (high vs. low)	1.875 (1.085–3.240)	0.024
Age (years) (≥65 vs. <65)	0.806 (0.509–1.276)	0.358
Sex (female vs. male)	1.245 (0.759–2.040)	0.385
Smoking (yes vs. no)	1.191 (0.743–1.911)	0.468
Drinking (yes vs. no)	1.179 (0.699–1.990)	0.537
Weight loss (yes vs. no)	1.226 (0.771–1.951)	0.390
Family history (yes vs. no)	2.258 (1.274–4.004)	0.005
Tumor location
Total stomach (ref)	Ref
Distal gastric cancer	0.355 (0.159–0.793)	0.011
Proximal gastric cancer	0.347 (0.148–0.818)	0.015
Borrmann type (I/II vs. III/IV)	0.587 (0.369–0.933)	0.024
Lauren type
Mixed (ref)	Ref
Diffuse	0.660(0.334–1.305)	0.232
Intestinal	0.494(0.255–0.956)	0.036
Grade of differentiation (poor/well vs. moderate-poor/moderate)	0.957(0.597–1.533)	0.854
Pathological type (signet ring cell carcinoma/mucinous adenocarcinoma vs. adenocarcinoma)	0.680 (0.295–1.570)	0.367
Tumor size (cm) (≥5 cm vs. <5 cm)	1.358 (0.816–2.263)	0.239
T stage (T1/T2 vs. T3/T4)	0.369 (0.090–1.507)	0.165
N stage (N0 vs. N1/n2/n3)	0.655 (0.205–2.092)	0.475
M stage (M0 vs. M1)	0.266 (0.141–0.503)	<0.001
TNM stage (I/II/III vs. IV)	0.266 (0.141–0.503)	<0.001
Nerve invasion (positive vs. negative)	1.583 (0.884–2.838)	0.123
Vascular invasion (positive vs. negative)	2.046 (1.240–3.377)	0.005
AFP (ng/ml) (>8.1 vs. ≤8.1)	1.243 (0.538–2.870)	0.610
CA19-9 (U/ml) (>37 vs. ≤37)	1.469 (0.929–2.324)	0.222
PD-L1 (positive vs. negative)	1.071 (0.662–1.733)	0.779
CD3 (high vs. low)	0.646 (0.406–1.028)	0.065
CD4 (high vs. low)	0.538 (0.337–0.858)	0.009
CD8 (high vs. low)	0.625 (0.393–0.995)	0.048

^cStatistically significant ().